Krystal Biotech Inc annual ebitda for fiscal 2025 was $196 million, an increase of 78.2% from $110 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $196M | $110M | ($91M) | ($117M) | ($66M) | ($30M) | ($18M) | ($11M) | ($5M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $63M | $40M | $50M | $48M | $45M | $50M | $36M | $23M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More KRYS metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All KRYS financial statements → Interactive KRYS charts →
About TickerBase · Data methodology & sources · Privacy · Terms